day one biopharmaceuticals inc - DAWN
DAWN
Close Chg Chg %
21.44 -0.01 -0.02%
Open Market
21.44
-0.01 (0.02%)
Volume: 512.77K
Last Updated:
Apr 1, 2026, 12:48 PM EDT
Company Overview: day one biopharmaceuticals inc - DAWN
DAWN Key Data
| Open $21.44 | Day Range 21.42 - 21.44 |
| 52 Week Range 5.64 - 21.46 | Market Cap $2.21B |
| Shares Outstanding 103.30M | Public Float 75.85M |
| Beta -1.75 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.04 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 7.91M |
DAWN Performance
| 1 Week | 0.14% | ||
| 1 Month | 102.26% | ||
| 3 Months | 130.04% | ||
| 1 Year | 196.95% | ||
| 5 Years | N/A |
DAWN Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About day one biopharmaceuticals inc - DAWN
Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.
DAWN At a Glance
Day One Biopharmaceuticals, Inc.
1800 Sierra Point Parkway
Brisbane, California 94005
| Phone | 1-650-484-0899 | Revenue | 158.18M | |
| Industry | Pharmaceuticals: Major | Net Income | -107,322,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 20.601% | |
| Fiscal Year-end | 12 / 2026 | Employees | 178 | |
| View SEC Filings |
DAWN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 6.081 |
| Price to Book Ratio | 2.176 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.223 |
| Enterprise Value to Sales | 3.31 |
| Total Debt to Enterprise Value | 0.005 |
DAWN Efficiency
| Revenue/Employee | 888,662.921 |
| Income Per Employee | -602,932.584 |
| Receivables Turnover | 5.917 |
| Total Asset Turnover | 0.29 |
DAWN Liquidity
| Current Ratio | 8.015 |
| Quick Ratio | 7.911 |
| Cash Ratio | 7.288 |
DAWN Profitability
| Gross Margin | 89.12 |
| Operating Margin | -80.761 |
| Pretax Margin | -69.096 |
| Net Margin | -67.847 |
| Return on Assets | -19.681 |
| Return on Equity | -22.74 |
| Return on Total Capital | -24.174 |
| Return on Invested Capital | -22.615 |
DAWN Capital Structure
| Total Debt to Total Equity | 0.633 |
| Total Debt to Total Capital | 0.629 |
| Total Debt to Total Assets | 0.55 |
| Long-Term Debt to Equity | 0.594 |
| Long-Term Debt to Total Capital | 0.59 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Day One Biopharmaceuticals Inc - DAWN
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | 131.16M | 158.18M | - |
Sales Growth
| - | - | - | +20.60% | - |
Cost of Goods Sold (COGS) incl D&A
| 531.00K | 383.00K | 5.28M | 17.21M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 531.00K | 383.00K | 2.03M | 3.79M | |
Depreciation
| 531.00K | 383.00K | 559.00K | 676.00K | |
Amortization of Intangibles
| - | - | 1.47M | 3.11M | - |
COGS Growth
| +166.83% | -27.87% | +1,278.33% | +226.01% | |
Gross Income
| (531.00K) | (383.00K) | 125.88M | 140.97M | |
Gross Income Growth
| -166.83% | +27.87% | +32,967.36% | +11.99% | |
Gross Profit Margin
| - | - | +95.98% | +89.12% | - |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 146.38M | 205.68M | 343.15M | 268.72M | |
Research & Development
| 85.62M | 130.52M | 227.70M | 148.13M | |
Other SG&A
| 60.76M | 75.16M | 115.45M | 120.59M | |
SGA Growth
| +101.78% | +40.51% | +66.84% | -21.69% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (146.91M) | (206.06M) | (217.27M) | (127.75M) | |
Non Operating Income/Expense
| 4.73M | 17.15M | 128.92M | 18.45M | |
Non-Operating Interest Income
| 4.75M | 17.19M | 19.70M | 18.47M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (142.18M) | (188.92M) | (88.35M) | (109.30M) | |
Pretax Income Growth
| -95.43% | -32.87% | +53.23% | -23.71% | |
Pretax Margin
| - | - | -67.36% | -69.10% | - |
Income Tax
| - | - | 7.14M | (1.98M) | - |
Income Tax - Current - Domestic
| - | - | 7.14M | (1.98M) | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (142.18M) | (188.92M) | (95.50M) | (107.32M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (142.18M) | (188.92M) | (95.50M) | (107.32M) | |
Net Income Growth
| -101.26% | -32.87% | +49.45% | -12.38% | |
Net Margin Growth
| - | - | -72.81% | -67.85% | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (142.18M) | (188.92M) | (95.50M) | (107.32M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (142.18M) | (188.92M) | (95.50M) | (107.32M) | |
EPS (Basic)
| -2.1718 | -2.3682 | -1.0243 | -1.0399 | |
EPS (Basic) Growth
| +21.15% | -9.04% | +56.75% | -1.52% | |
Basic Shares Outstanding
| 65.47M | 79.77M | 93.23M | 103.21M | |
EPS (Diluted)
| -2.1718 | -2.3682 | -1.0243 | -1.0399 | |
EPS (Diluted) Growth
| +21.15% | -9.04% | +56.75% | -1.52% | |
Diluted Shares Outstanding
| 65.47M | 79.77M | 93.23M | 103.21M | |
EBITDA
| (146.38M) | (205.68M) | (215.24M) | (123.96M) | |
EBITDA Growth
| -101.78% | -40.51% | -4.65% | +42.41% | |
EBITDA Margin
| - | - | -164.10% | -78.37% | - |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 21.50 | |
| Number of Ratings | 8 | Current Quarters Estimate | -0.178 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | -0.78 | |
| Last Quarter’s Earnings | -0.23 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.04 | Next Fiscal Year Estimate | -0.185 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 9 | 9 | 9 | 8 |
| Mean Estimate | -0.18 | -0.16 | -0.78 | -0.18 |
| High Estimates | -0.03 | -0.01 | -0.16 | 0.35 |
| Low Estimate | -0.26 | -0.30 | -2.02 | -0.63 |
| Coefficient of Variance | -46.02 | -52.87 | -68.81 | -196.55 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 0 | 0 | 9 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 8 | 8 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Hold | Hold | Buy |
SEC Filings for Day One Biopharmaceuticals Inc - DAWN
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Day One Biopharmaceuticals Inc - DAWN
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 20, 2025 | Charles N. York COO and CFO | 285,527 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Lauren Merendino Chief Commercial Officer | 44,252 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Adam Dubow Gen Counsel & Secretary | 59,571 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Adam Dubow Gen Counsel & Secretary | 57,821 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Charles N. York COO and CFO | 79,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Charles N. York COO and CFO | 53,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Charles N. York COO and CFO | 9,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Charles N. York COO and CFO | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Charles N. York COO and CFO | 294,715 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.91 per share | 2,625,910.65 |
| Nov 20, 2025 | Charles N. York COO and CFO | 298,777 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Charles N. York COO and CFO | 292,152 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Jeremy Bender CHIEF EXECUTIVE OFFICER; Director | 164,935 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Charles N. York COO and CFO | 283,277 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Jeremy Bender CHIEF EXECUTIVE OFFICER; Director | 140,252 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Jeremy Bender CHIEF EXECUTIVE OFFICER; Director | 93,504 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Jeremy Bender CHIEF EXECUTIVE OFFICER; Director | 19,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Jeremy Bender CHIEF EXECUTIVE OFFICER; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Jeremy Bender CHIEF EXECUTIVE OFFICER; Director | 177,165 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.91 per share | 1,578,540.15 |
| Nov 20, 2025 | Jeremy Bender CHIEF EXECUTIVE OFFICER; Director | 193,059 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 20, 2025 | Jeremy Bender CHIEF EXECUTIVE OFFICER; Director | 181,372 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |